Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

What was studied

This study looked at gene changes in older people with mantle cell lymphoma. The people took part in FIL V-RBAC, a phase 2 trial. Of 140 people enrolled, 132 had DNA from lymph node or bone marrow samples. A test of 146 genes looked for gene mutations and copy number changes. The team linked the findings to progression-free survival.

What they found

ATM was the gene mutated most often, in 55 people. TP53 and KMT2D were each mutated in 31 people. Beyond TP53, 3 other changes were independently tied to progression-free survival. Those were single-hit ATM changes, CDKN2A loss and CD36 mutations. People with single-hit ATM changes and no other risk factors had lasting remission. CD36 mutations went with worse survival. The team combined 4 factors into a model. It split people into 4 groups with different outcomes.

What it means for patients

The authors say the findings support molecular testing in this lymphoma. They also support risk-adapted trials such as FIL V-RBAC. They say other markers should be combined with TP53 mutations for more precise risk assessment.

Why it is not certain yet

The model was checked only inside this group, by a bootstrapping method. The abstract does not say whether it holds in other groups. The 2 new findings were seen in this one cohort. The links shown do not prove cause.

Source

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.